Full-Time

Executive Director / Vice President

Biopharma

Posted on 9/25/2025

Thermo Fisher Scientific

Thermo Fisher Scientific

10,001+ employees

Supplies laboratory instruments, reagents, diagnostics

No salary listed

North Carolina, USA

Remote

Category
Biology & Biotech (7)
, , , , , ,
Required Skills
Sales
Salesforce
Requirements
  • A bachelor’s degree in business administration, sales, or a related field is the required minimum education; MBA or advanced degree is preferred.
  • Previous experience that provides the knowledge, skills, and abilities to perform the job comparable to 15+ years; strong preference for experience in a CRO, Pharmaceutical or Medical Device sales industry.
  • Proven sales history with breadth of domestic geographic responsibility and 5+ years of account management experience.
  • Demonstrated success in a similar commercial leadership role that has consistently achieved and exceeded commercial targets.
  • In-depth knowledge of the CRO industry and clinical trial processes, including regulatory requirements and best practices.
  • Strong understanding of complex technical requirements and the ability to effectively communicate technical information to both technical and non-technical stakeholders.
  • Excellent leadership and communication skills, with the ability to effectively collaborate, cultivate and influence stakeholders across functions and at all levels.
  • Demonstrates robust judgment, problem solving and decision making; Ability to apply critical and analytical thinking and business acumen to develop effective solutions.
  • A “big-picture” thinker with the ability to contribute meaningfully to strategic discussions while also remaining attuned to the details required for successful operational execution.
  • Ability to create constructive tension with customers by identifying customer challenges and potential gaps, designing customized solutions and messaging to influence customer behavior and influence the buying process.
  • Understanding of management, planning, organizing and resourcing skills and managing priorities. A high tolerance for ambiguity and the ability to navigate complexity.
  • Great communicator and negotiator, able to develop shared perspectives and achieve actionable results through others.
  • Ability to handle complex situations and multiple responsibilities simultaneously mixing long term projects with the urgency of immediate demands on the operations.
  • Demonstrated analytical skills with the ability to judge situations accurately and quickly, grasping complexities, identifying key issues and applying sound judgment.
  • Ability to quickly and effectively build credibility and strong relationships at all levels.
  • Strategic thinker with ability to uncover and understand customer needs and construct novel enterprise level solutions to address customer needs.
  • Must show the ability to demonstrate the Thermo Fisher values (The Four I’s) – Integrity, Intensity, Innovation, and Involvement.
Responsibilities
  • Cultivate and expand deep relationships at the highest levels within the account working in close coordination with your direct reports and other departments.
  • Establish and grow customer loyalty and Customer Delight, including proactively engaging customers with insights on industry trends and potential challenges to position proactive innovative solutions to overcome them.
  • Drive engagement between Executive Sponsor and other senior executives within broader Thermo Fisher leadership to foster deep trust and confidence in CRG’s offerings while gaining business insights to accelerate expansion.
  • Make connections and identify new account areas for potential footprint expansion.
  • Build and strengthen client advocacy and engagement at the highest account organizational levels.
  • Establish robust CRG stakeholder management across all business units.
  • Drive team to achieve target within CDSD and all CRG business units.
  • Expand existing commercial presence to grow account into strategic partner.
  • Central point of contact for internal and external communication across all CRG.
  • Proactively engages and drive internal stakeholders across the TMO organization (CRG, PSG, other groups), direct reports, and business partners (Finance, Legal, Sales, Operational Delivery, Governance) to ensure operational, financial and commercial goals are achieved.
  • Coaches team and is actively involved on proposals and bid defenses and owns partnership pursuits efforts within account.
  • Develop and maintain active account plan and demonstrate progress against planned strategies.
  • Proactively solicits feedback from internal and external stakeholders to capture business intelligence for all account team members to share intelligence, best practices, and drive competitive differentiation.
  • Identifies key areas of strategic expansion within account and drives proactive selling across all business units within CRG and across PSG.
  • Collaborates with therapeutic unit leadership to develop strategies and execute against account growth plan with emphasis on enterprise level view.
  • Develops innovative commercial solutions (including commercial constructs, financial incentive structures, operational models) and proactively presents to customer to address existing challenges.
  • Proactively identify and address financial, operational, relationship and quality concerns aligned with customer needs while emphasizing TMO’s market differentiation.
  • Develops strong working relationships with internal operational, commercial and finance partners to execute according to plan.
  • Prioritize top revenue generation and maximize to increase market penetration.
  • Enterprise champion collaborating effectively with direct reports and operational colleagues to ensure exquisite operational delivery, exceed operational milestones while maintaining expected levels of quality and rigor.
  • Coach Dev Ops and others to proactively address potential challenges and issues while optimizing existing operating models to support more efficient ways of working.
  • Leverage collective relationship to identify customer needs to inform innovation and investment strategies.
  • Demonstrates a deep understanding of the client’s market position, needs, and competitive landscape consistently with ability to influence internal commercial, technological and operational innovation to proactively reduce gaps and drive transformation.
  • Deeply understand industry trends to inform clients.
  • Challenge enterprise on client needs to force innovation discussion and application to proactively reduce gaps and drive process improvements.
  • Recruit, train, and manage the high-performing account team, including business development and development operations.
  • Foster a collaborative and motivated environment focused on accountability for results, client advocacy and innovative problem solving by providing rigorous oversight, coaching and guidance to maximize individual and team performance using Challenger methodology.
  • Ensure consistent delivery for each business development representative of top-line sales goals and targeted profit contribution.
  • Drives commercial execution excellence.
  • Correctly use Salesforce and enforce all sales administrative tasks.
Desired Qualifications
  • MBA or advanced degree is preferred.
  • Strong preference for experience in a CRO, Pharmaceutical or Medical Device sales industry.
Thermo Fisher Scientific

Thermo Fisher Scientific

View

Thermo Fisher Scientific provides life sciences tools and services for research, healthcare, and industry. Its products include laboratory instruments, reagents, consumables, and software for activities like protein biology, PCR, sequencing, and bioprocessing. It differentiates itself with an end-to-end footprint across trusted brands and strong customer support and education, plus direct sales and promotions. Its goal is to help make the world healthier, cleaner, and safer by enabling discovery, diagnostics, and quality manufacturing across research institutions, healthcare providers, and government bodies.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Simplify Jobs

Simplify's Take

What believers are saying

  • Orbitrap Apex and Excedion can lift premium instrument demand in proteomics.
  • Workflow bundles around oligonucleotides, mRNA, and PFAS create stickier recurring revenue.
  • Olink and biobank programs expand Thermo Fisher into population-scale translational research.

What critics are saying

  • Danaher, Waters, and Agilent pressure Thermo Fisher in high-margin analytical workflows.
  • Organic growth above 7% lacks support, and margins have already deteriorated.
  • Shared-access cryo-EM centers lose value if customers buy in-house microscopes.

What makes Thermo Fisher Scientific unique

  • Thermo Fisher pairs Orbitrap hardware with AI software from MSAID and Proteinaceous.
  • Its 2026 launches target research, biopharma, and regulated testing workflows.
  • The Gothenburg lab and South San Francisco center deepen customer access before purchase.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Thermo Fisher Scientific who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Fertility Treatment Support

Family Planning Benefits

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Company News

FinancialContent
May 4th, 2026
Thermo Fisher Scientific unveils an integrated platform to advance scalable Cell Therapy manufacturing.

Thermo Fisher Scientific unveils an integrated platform to advance scalable Cell Therapy manufacturing. Published at May 4th 2026, 8:30 AM EDT via Business Wire i This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. New Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies for cancer, autoimmune, and other treatments Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to scalable, automation-ready platforms that can support consistent quality, cost control, and cGMP compliance. Developers must balance process flexibility with the operational demands of clinical manufacturing, often within limited facility space and tight development timelines. At the same time, the cell therapy landscape continues to evolve beyond oncology into a broader range of indications, including autoimmune and other emerging areas. This shift is driving the development of new cell modalities and diverse manufacturing approaches. These emerging applications often require different process configurations and production scales, adding complexity to manufacturing strategies across all stages of development and commercialization. The CTS DynaXS Single Use Bioreactor was designed specifically to address these evolving needs. The stirred-tank, single-use system supports cell expansion across development and early clinical volumes, offering a scalable platform from small process development batches to larger cGMP manufacturing runs. "Cell therapy manufacturers are navigating a rapidly expanding pipeline and increasing regulatory expectations," said Sara Henneman, vice president and general manager of Thermo Fisher Scientific's cell culture and cell therapy business. "The CTS DynaXS bioreactor reflects our commitment to help deliver end-to-end, integrated solutions that enable customers to simplify scale-up, strengthen process control, and support the development of therapies intended for patient use." Integrated Within the CTS Cell Therapy Ecosystem The CTS DynaXS bioreactor extends Thermo Fisher's Cell Therapy Systems (CTS) portfolio, supporting workflows from cell isolation and activation through expansion and downstream processing. This integration enables customers to build modular, scalable manufacturing strategies with unified technical support and regulatory documentation. "Manufacturers want platforms that grow with them," said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. "With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types." Thermo Fisher's Commitment to Cell Therapy Innovation Spans Over 20 Years As demand for scalable, reproducible cell therapy manufacturing solutions accelerates, Thermo Fisher remains committed to supporting customers with technologies designed to reduce complexity, enhance control, and support progress toward clinical development. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. Contacts. Report this content If you believe this article contains misleading, harmful, or spam content, please let us know.

Yahoo Finance
Apr 14th, 2026
Thermo Fisher expands precision health push with HealthVerity data access covering 270M patients

Thermo Fisher Scientific has announced multiple collaborations strengthening its precision health capabilities, including a data partnership with HealthVerity providing access to claims data on over 270 million de-identified US patients across 70 linked sources. The company has also launched proteomics initiatives and new cell therapy tools. The HealthVerity collaboration enhances Thermo Fisher's PPD unit's real-world evidence and trial optimisation services, supporting its ambition to serve as an end-to-end partner in clinical development. The moves deepen the company's integration of large-scale data, high-throughput proteomics and automated manufacturing across the biopharma value chain. The company's narrative projects $50 billion revenue and $9 billion earnings by 2028, requiring 5% annual revenue growth. However, investors face risks from potential margin pressure due to tariffs and policy uncertainty.

The Journal of Healthcare Contracting
Apr 13th, 2026
Thermo Fisher Scientific's PPD clinical research business forms data-focused collaboration.

Thermo Fisher Scientific's PPD clinical research business forms data-focused collaboration. April 13, 2026- Thermo Fisher Scientific announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD(TM) clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy(R) claims dataset, representing more than 270 million de-identified patient lives across the U.S. healthcare system. The datasets will provide deep insights into disease prevalence, treatment patterns and provider activity, further strengthening the clinical research business' data and AI driven services across trial feasibility and optimization, recruitment and real-world evidence generation. The agreement also provides access to a marketplace of more than 70 curated data sources, including electronic medical records, laboratory results and other specialty datasets. With streamlined access to longitudinal claims and linked datasets, the business can deliver more precise site selection strategies and improved startup timelines.

Yahoo Finance
Apr 12th, 2026
Thermo Fisher joins Singapore's PRECISE SG100K biobank project for Asia-Pacific precision medicine research

Thermo Fisher Scientific has partnered with Singapore's PRECISE to support the PRECISE SG100K biobank initiative. The company will supply integrated multi-platform proteomics capabilities, including Olink PEA and Orbitrap Astral mass spectrometry, alongside partners Seer and Novogene. The collaboration aims to support population-scale precision medicine research and biomarker discovery across the Asia Pacific region. The stock currently trades at $496.11, approximately 32.7% below the analyst target of $658.40. Thermo Fisher's Life Sciences segment generates $44.6 billion in revenue, with a P/E ratio of 27.5x compared to the industry average of 37.3x. However, analysts note earnings have declined 5% annually over five years, and debt coverage by operating cash flow remains a concern.

PR Newswire Asia
Apr 10th, 2026
NovogeneAIT Genomics appointed as service provider to advance large-scale proteomics for PRECISE-SG100K cohort in Singapore.

NovogeneAIT Genomics appointed as service provider to advance large-scale proteomics for PRECISE-SG100K cohort in Singapore. 2026-04-10 12:44 551 SINGAPORE, April 10, 2026 /PRNewswire/ - NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by Thermo Fisher Scientific in collaboration with PRECISE to support precision medicine research in Singapore. This landmark project will utilize Thermo Fisher Scientific's Orbitrap Astral mass spectrometry platform, coupled with Seer's Proteograph Product Suite and Olink's Reveal Assay. Together, these advanced technologies will enable deep proteomic profiling of 10,000 samples. This study aims to demonstrate the profound value of deep, unbiased plasma proteomics, enabling high-throughput analysis and the discovery of novel biomarkers and biological signatures associated with aging and disease. "Being appointed as the service lab for this landmark study represents a major leap forward in our capability to support large-scale proteomics research in Singapore," said John Zhang, Senior Commercial director of NovogeneAIT. Together, with Thermo Fisher Scientific and Seer, Polkadot PR Pty Ltd is uniquely positioned to deliver deep, actionable insights from this cohort and contribute meaningfully to Singapore's National Precision Medicine Program." Prof. John Chambers, Chief Scientific Officer at PRECISE and lead Principal Investigator of the PRECISE-SG100K cohort, highlighted the importance of this partnership: "This collaboration further strengthens the PRECISE-SG100K dataset, through addition of mass spectroscopy based assessment of proteomic variation. The results will enable our researchers to carry out integrated analyses across different layers of biology. Such efforts are important for improving our understanding of disease mechanisms and supporting future translational research." The successful completion of this 10,000 sample pilot study is expected to serve as a robust proof of concept. It will demonstrate the immense value of complementary proteomics and support the broader expansion of a multi-omics approach for the PRECISE-SG100K cohort. About NovogeneAIT Genomics NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. Established as a joint venture between Novogene and AITbiotech, it has grown to become one of the largest multi-omics service providers in Southeast Asia. The company offers a comprehensive suite of services, including genomics, transcriptomics, single cell and spatial transcriptomics, metagenomics and proteomics. NovogeneAIT Genomics delivers high-quality omics solutions to support research across various sectors, including healthcare and agriculture. About PRECISE-SG100K The PRECISE-SG100K study is a landmark long-term research project that has successfully completed its recruitment phase, having engaged over 100,000 participants from Singapore's diverse, multi-ethnic population. This comprehensive study has collected extensive baseline health information and biological specimens from participants across the nation. Moving forward, the study will continue to monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension, and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K represents a significant milestone for health research in Singapore and is positioned to yield globally significant results that will advance precision medicine and improve health outcomes for diverse populations worldwide. For more information, please visit Phase II: PRECISE SG100K.

INACTIVE